Grammer. Enfermedades alérgicas 8 ed

CAPÍTULO 38 • NUEvOS TRATAMIENTOS INMUNOLÓGICOS, INCLUIDOS LOS BIOLÓGICOS 797

24. Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody in moderate to severe asthma. Am J Respir Crit Care Med . 2013;188:1294-1302. 25. Kabata H, Moro K, Koyasu S, et al. Mechanisms to suppress ILC2-induced airway inflammation. Ann Thorac Soc . 2016;(Suppl 1):S95. 26. Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allegen-induced asthmatic respon- ses. N Engl J Med . 2014;370:2102-2110. 27. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol . 2008;121(1):5-10. 28. Jacobi A, Antoni C, Manger B, et al. Infliximab in the treat- ment of moderate to severe atopic dermatitis. J Am Acad Dermatol . 2005;52:522-526. 29. Leiding JW, Holland SM. Chronic granulomatous disea- se. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. GeneReviews . Seattle, WA: University of Washington, 2012:1993-2016. 30. Pung YH, Vetro SW, Bellanti JA. Use of interferons in atopic (IgE-mediated) diseases. Ann Allergy . 1993;71:234-238. 31. Jang IG, Yang JK, Lee HJ, et al. Clinical improvement and immunohistochemical findings in severe atopic derma- titis treated with interferon gamma. J Am Acad Dermatol . 2000;42(6):1033-1040. 32. Pruitt JR, Batt DA, Wacker LL, et al. CC chemokine receptor-3 (CCR3) antagonists: improving the selectivivty of DPC168 by reducing central ring lipophilicity. Bioorg Med Chem Lett . 2007;17:2992-2997. 33. Santella JB III, Gardner DS, Yao W, et al. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part 1: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition poten- cy against eosinophil chemotaxis. Bioorg Med Chem Lett . 2008;18:576-585. 34. Cahn A, Hodgson S, Wilson R, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study. BMC Pharmacol Toxicol . 2013;14:14-22. 35. Adcock IM, Chung KF, Caramori K, et al. Kinase inhibi- tors and airway inflammation. Eur J Pharmacol . 2006;533 (1-3):118–132. 36. Ramis R, Otal C, Carreno A, et al. A novel inhaled Syk inhibitor blocks mast cell degranulation and early asthmatic response. Pharmacol Res . 2015;99:116-124.

38. Kuperman D, Schofield B, Wills-Karp M, et al. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med . 1998;187:939-948. 39. Caramori G, Groneberg K, Ito K, et al. New drugs tar- geting Th2 lymphocytes in asthma. J Occup Med Toxicol . 2008;3(Suppl 1):S6. 40. Erpenbeck VJ, Popov TA, Miller D, et al. Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma. Data Brief . 2016;9:199-205. 41. Kuna P, Bjermer L, Tomling G. Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma. Drug Des Devel Ther . 2016;10:2759-2770. 42. Ramrarine SI, Haddad EB, Khawaja AM, et al. On muscari- nic control of neurogenic mucus secretion in ferret trachea. J Physiol . 1996;494:577-586. 43. Gavalda A, Garcia-Gil E. Aclidinium bromide, a novel long-acting muscarinic antagonist (LAMA). Prog Respir Res . 2010;39:33-38. 44. Busse WW, Dahl R, Jenkins C, et al. Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma? Eur Respir Rev . 2016;139:54-64. 45. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J . 2009;34:757-769. 46. Ley K. Functions of selectins. Results Probl Cell Differ . 2001;33:177-200. 47. Gross NJ. The COPD pipeline XXII. COPD . 2013;10:390–392. 48. Sundahl N, Bridelance J, Libert C. Selective glucocorticoid receptor modulation: new directions with non-steroidal scaffolds. Pharmacol Ther . 2015;152:28-41. 49. Doggrell S. Is AL-438 likely to have fewer side effects than the glucocorticoids? Expert Opin Investig Drugs . 2003;12:1227-1229. 50. Robinett KS, Koziol-White CJ, Akoluk A, et al. Bitter taste receptor function in asthmatic and non-asthmatic human airway smooth muscle cells. Am J Respir Cell Mol Biol . 2014;50:678-683. 51. FAO/WHO. Health and Nutritional Properties of Probiotics in Food. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food. 2001. 52. Koletzko S. Probiotics and prebiotics for prevention of food allergy: indications and recommendations by societies and institutions. J Pediatr Gastroenterol Nutr . 2016;63:S9-S10. 53. Prescott SL, Bjorksten B. Probiotics for the prevention or treatment of allergic diseases. J Allergy Clin Immunol . 2007;120:255-262. 54. Sweileh WM, Shraim NY, Al-Jabi SW, et al. Assessing worldwide research activity on probiotics in pediatrics using Scopus database: 1994–2014. World Allergy Organ J . 2016;9:25-37.

37. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of allergic rhinitis in a park environment. J Allergy Clin Immunol . 2005;115:791-796. SAMPLE